Tarsus Pharmaceuticals, Inc. TARS Performance stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan (in shares)
Performance stock units issued and outstanding (unvested) under 2020 Equity Incentive Plan (in shares) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CommonStockCapitalSharesReservedForFutureIssuanceEffectOfPerformanceStockUnitsAvailableForFutureGrants.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under 2020 equity incentive plan (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s performance stock units issued and outstanding (unvested) under 2020 equity incentive plan (in shares)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported performance stock units issued and outstanding (unvested) under 2020 equity incentive plan (in shares) of 724.8K in Q4 2025.
- What does performance stock units issued and outstanding (unvested) under 2020 equity incentive plan (in shares) mean?
- This metric tracks the number of unvested performance stock units (PSUs) currently outstanding under the company's equity incentive plan. Unlike standard options, these units typically vest based on the achievement of specific corporate performance goals. It highlights the company's use of performance-based incentives to align employee interests with long-term shareholder value.